Treatment Strategies in Chronic Leukemias and Introduction to CAR-T Therapy

Access Activity

Overview / Abstract:

Chronic lymphocytic (CLL) and chronic myelogenous (CML) leukemia are commonly diagnosed and treated by community oncologists. Whereas, in the past, these hematologic malignancies were considered incurable, new therapies have challenged that notion.
Tyrosine kinase inhibitors (TKIs) annihilated the concept of CML as a poorly controlled disease, and most patients are now expected to live a normal life, with good quality of life. New testing procedures have suggested that some patients may be “cured,” such that ongoing chronic pharmaceutical intervention may be interrupted or discontinued. Identifying new targets in CLL has similarly changed the paradigm of intervention to the possibility of “cure” using a more aggressive and multiagent approach.
A new form of immunotherapy, using CAR-T cells, initially used in acute leukemias, now appears to be applicable to CLL as well, with encouraging results. New molecular tests to identify subsets of patients who may benefit from targeted interventions have also improved the chances of success in treating chronic leukemias. This webcourse will review new concepts in diagnosis and treatment of CLL and CML.

Educational Objectives
At the conclusion of this session, participants should be able to demonstrate the ability to:

-Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care

-Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with chronic leukemia

-Discuss current recommendations for diagnostic testing for chronic leukemia to facilitate treatment selection

-Assess the safety and efficacy of approved and emerging therapies for primary and subsequent management of chronic leukemia with attention to cost/benefit and toxicity considerations

-Employ resources to increase patient access and engagement

Expiration

Jan 24, 2019

Discipline(s)

Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME

Format

Webinar / Webcast / Video

Credits / Hours

AACME - 1.00 AMA PRA Category 1 Credit; ACPE - 1.00 hours (0.1 CEUs); ANCC - 1.1 contact hours; APRN - 0.3 contact hours pharmacology credit

Accreditation

Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology

Presenters / Authors / Faculty

Saar Gill, MD, PhD
Assistant Professor of Medicine
Division of Hematology‐Oncology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Activity Specialities / Related Topics

Pharmacology, Oncology / Cancer / Radiation Therapy, Nutrition / Dietary, Immunology / Immunosuppression, Hematology, Genetics, Administration / Management

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Keywords / Search Terms

Rockpointe, chronic lymphocytic leukemia, CLL, chronic myelogenous leukemia, CML,Tyrosine kinase inhibitors, TKIs, immunotherapy, CAR-T cells, oncology, hematology, tumor types, CAR-T therapy,PCME, Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map